Company Filing History:
Years Active: 2008-2011
Title: The Innovative Contributions of Min Ge
Introduction
Min Ge is a notable inventor based in Edison, NJ (US), recognized for his significant contributions to the field of medicinal chemistry. He holds a total of 4 patents, focusing primarily on antidiabetic compounds that target G-protein coupled receptor 40 (GPR40). His work is particularly relevant in the context of treating Type 2 diabetes mellitus and associated conditions.
Latest Patents
Among his latest patents, Min Ge has developed antidiabetic bicyclic compounds that include diaryl ethers. These compounds feature one aryl group that is a phenyl fused to a cycloalkyl or heterocyclic ring, with an acetic acid group attached. They serve as agonists of GPR40 and are useful therapeutic agents for Type 2 diabetes and related conditions such as insulin resistance, obesity, and lipid disorders. Another patent involves bicyclic compounds containing a phenyl or pyridyl ring fused to a cycloalkyl or heterocyclic ring, which also includes a 5-membered heterocyclic ring. These compounds, along with their pharmaceutically acceptable salts and prodrugs, are similarly aimed at treating Type 2 diabetes and its associated complications.
Career Highlights
Min Ge has had a distinguished career, working with prominent companies in the pharmaceutical industry. He has been associated with Merck Sharp & Dohme Corporation and Merck & Company, Inc., where he has contributed to the development of innovative therapeutic solutions.
Collaborations
Throughout his career, Min Ge has collaborated with esteemed colleagues, including Lihu Yang and Changyou Zhou. Their combined expertise has further advanced the research and development of effective treatments for diabetes and related health issues.
Conclusion
Min Ge's innovative work in the field of antidiabetic compounds highlights his commitment to improving health outcomes for individuals with Type 2 diabetes. His patents and collaborations reflect a significant contribution to medicinal chemistry and therapeutic development.